Guided Therapeutics (GTHP) FCF Margin (2011 - 2025)

Guided Therapeutics has disclosed FCF Margin across 15 years of filings, most recently posting 49.32% for Q4 2025.

• FCF Margin for Q4 2025 came in at 49.32%, up 3315068.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 139.24% (up 1584647.0% YoY), and the FY2025 annual result was 139.5%, up 1584621.0% from the prior year.
• FCF Margin came in at 49.32% for Q4 2025 at Guided Therapeutics, up from 461.67% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 258.33% in Q4 2021 to a low of 34800.0% in Q2 2021.
• The 5-year median for FCF Margin is 1967.42% (2023), against an average of 7840.94%.
• Across the five-year window, FCF Margin slumped 3215000 bps in 2024 and surged 3315068 bps in 2025, its largest moves.
• Guided Therapeutics' FCF Margin stood at 258.33% in 2021, then plunged by 7958 bps to 20300.0% in 2022, then jumped by 95 bps to 1050.0% in 2023, then sank by 3062 bps to 33200.0% in 2024, then jumped by 100 bps to 49.32% in 2025.
• The last three FCF Margin figures came in at 49.32% (Q4 2025), 461.67% (Q3 2025), and 144.44% (Q2 2025), per Business Quant data.